STOCK TITAN

MapLight (MPLT) CFO reports tax withholding on RSU settlement

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics Chief Financial Officer reports routine tax-related share withholding. On January 27, 2026, 33,382 shares of voting common stock were withheld by the company at $17.98 per share to cover tax obligations tied to a restricted stock unit settlement.

After this transaction, the CFO beneficially owned 387,819 shares directly. The remaining securities are still subject to a lock-up agreement linked to MapLight’s initial public offering, restricting most transfers for 180 days after the final prospectus dated October 26, 2025.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Setia Vishwas

(Last) (First) (Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE

(Street)
REDWOOD CITY CA 94063

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Voting Common Stock 01/27/2026 F 33,382(1) D $17.98 387,819 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of a restricted stock unit award. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.
/s/ Kristopher L. Hanson, Attorney-in-Fact 01/29/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MapLight Therapeutics (MPLT) report in this Form 4?

MapLight Therapeutics reported its Chief Financial Officer had 33,382 shares of voting common stock withheld on January 27, 2026. These shares were retained by the issuer to satisfy tax withholding obligations related to the settlement of a restricted stock unit award.

At what price were the withheld MapLight (MPLT) shares valued in the transaction?

The 33,382 voting common stock shares were valued at $17.98 per share in the reported transaction. This price is used solely to calculate the value of shares withheld to satisfy tax obligations from a restricted stock unit settlement, not an open-market sale.

How many MapLight (MPLT) shares does the CFO own after this Form 4 transaction?

Following the tax-withholding transaction, the Chief Financial Officer beneficially owns 387,819 shares of MapLight voting common stock. This amount is reported as directly owned and reflects holdings after the restricted stock unit settlement and related share withholding.

Why were MapLight (MPLT) shares withheld from the CFO in this filing?

The filing explains that 33,382 shares were withheld by MapLight to cover tax withholding obligations. This occurred in connection with the settlement of a restricted stock unit award, meaning the shares were used to pay taxes rather than sold in the open market.

Is the MapLight (MPLT) CFO still under an IPO lock-up agreement?

Yes. The securities retained by the CFO remain subject to a lock-up agreement with the IPO underwriters. The agreement generally restricts selling or transferring issuer securities for 180 days after the final IPO prospectus dated October 26, 2025, subject to specified exceptions.

Does this MapLight (MPLT) Form 4 indicate an open-market sale by the CFO?

No. The transaction is coded as tax withholding, where 33,382 shares were retained by the issuer to satisfy tax obligations. The explanation clarifies this was related to a restricted stock unit settlement, not a discretionary open-market sale of shares by the CFO.
MapLight Therapeutics, Inc.

NASDAQ:MPLT

MPLT Rankings

MPLT Latest News

MPLT Latest SEC Filings

MPLT Stock Data

712.36M
14.75M